Medtronic Is Separating Its Diabetes Business - Good News For Investors

Medtronic plc (NYSE:MDT) announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction – an initial minority IPO carve-out followed by a split-off of the remaining stake. The separation will be tax-free for the shareholders and is expected to be completed in the next 18 months.

The separation comes as Medtronic focuses on higher-margin, faster-growing businesses such as pulsed field ablation and renal denervation. The Diabetes segment, which contributed $2.75 billion or 8% of FY2025 revenue, has lagged behind peers in growth and profitability, facing stiff competition from companies like Dexcom (DXCM), Abbott (ABT), and Tandem Diabetes Care (TNDM).

Strategic Rationale

Diabetes business is predominantly B2C, ...